๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Compound trial record
Trackers Drugs Trial finder
Compound · clinical trials

Eribulin clinical trials

Also listed in trial records as Halaven
Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 23 trials in our China, USA, UK and India registers that name Eribulin as an intervention. Synced 25 Sep 2026
23Current trials
11Recruiting now
21Lead sponsors
4Country registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 โ€” Top 14 finalist
Compiled from ClinicalTrials.gov registry records ยท Last verified ยท Editorial standards
At a glance

Eribulin is named as an intervention in 23 current clinical trials in our China, USA, UK and India registers. 11 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is BioNTech SE (2). The most-studied condition is Breast Cancer.

Trials by status

  • Recruiting1148%
  • Not yet open417%
  • Active, closed835%

Trials by phase

  • Phase 31148%
  • Phase 2730%
  • Phase 1/2417%
  • Phase 114%
01

Clinical trials of Eribulin

23 trials
StudyPhaseStatusLead sponsorRegisters
A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)
NCT06263231 · ClinicalTrials.gov ↗ · Sarcoma,Soft Tissue
Phase 3 Recruiting Intensity Therapeutics, Inc. USA
A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
NCT06279364 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer
Phase 3 Recruiting Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. China
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
NCT06435429 · ClinicalTrials.gov ↗ · Metastatic HER2-positive Breast Cancer
Phase 3 Recruiting Jazz Pharmaceuticals UK, USA
Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer
NCT06889688 · ClinicalTrials.gov ↗ · Breast Cancer Stage IV, Triple -Negative Breast Cancer
Phase 3 Recruiting Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University China
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
NCT07173751 · Breast Neoplasms
Phase 3 Recruiting BioNTech SE UK, USA, China
YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer
NCT07461454 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic Breast Cancer
Phase 3 Recruiting MediLink Therapeutics (Suzhou) Co., Ltd. China
Organoid-based Functional Precision Therapy for Advanced Breast Cancer
NCT06102824 · ClinicalTrials.gov ↗ · HER2-negative Breast Cancer, Advanced Breast Cancer
Phase 2 Recruiting Guangdong Provincial People's Hospital China
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
NCT07007559 · ClinicalTrials.gov ↗ · Breast Cancer, Metastatic
Phase 2 Recruiting ALX Oncology Inc. UK, USA
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
NCT03424005 · Metastatic Breast Cancer
Phase 1/2 Recruiting Hoffmann-La Roche UK, USA
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
NCT05824975 · ClinicalTrials.gov ↗ · Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS)
Phase 1/2 Recruiting GI Innovation, Inc. USA
Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer
NCT06942234 · ClinicalTrials.gov ↗ · Inoperable Locally Advanced HER2-Negative Breast Cancer, Metastatic HER2-Negative Breast Cancer
Phase 1/2 Recruiting Jiangsu Alphamab Biopharmaceuticals Co., Ltd China
Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer
NCT06202313 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer
Phase 2 Not yet open Shengjing Hospital China
JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC
NCT06731153 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer (TNBC), Metastatic Breast Cancer
Phase 2 Not yet open Fudan University China
Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer)
NCT07255612 · ClinicalTrials.gov ↗ · Breast Cancer
Phase 2 Not yet open Sun Yat-sen University China
A Study of AL58805 in Advanced, Metastatic GYN, STS or Breast Cancers
NCT07811232 · ClinicalTrials.gov ↗ · Endometrial Neoplasms, Soft Tissue Sarcoma (STS), Breast Neoplasms
Phase 1/2 Not yet open Advenchen Pharmaceuticals, LLC. USA
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
NCT03734029 · ClinicalTrials.gov ↗ · Breast Cancer
Phase 3 Active, closed Daiichi Sankyo UK, USA, China
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
NCT05104866 · ClinicalTrials.gov ↗ · Breast Cancer
Phase 3 Active, closed AstraZeneca UK, USA, India, China
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01)
NCT06343948 · ClinicalTrials.gov ↗ · HR+HER2- Breast Cancer
Phase 3 Active, closed Sichuan Baili Pharmaceutical Co., Ltd. China
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02)
NCT06382142 · ClinicalTrials.gov ↗ · Triple-Negative Breast Cancer
Phase 3 Active, closed Sichuan Baili Pharmaceutical Co., Ltd. China
FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer
NCT06519370 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer
Phase 3 Active, closed Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. China
Tucatinib+Trastuzumab+Eribulin in HER2+ MBC
NCT05458674 · ClinicalTrials.gov ↗ · Breast Cancer, Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer
Phase 2 Active, closed Criterium, Inc. USA
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
NCT06449222 · ClinicalTrials.gov ↗ · Locally Advanced Breast Cancer, Triple Negative Breast Cancer, Metastatic Triple Negative Breast Cancers
Phase 2 Active, closed BioNTech SE UK, USA
ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
NCT06328738 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Positive Solid Tumors
Phase 1 Active, closed Enliven Therapeutics USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Conditions studied with Eribulin

29 conditions
Breast Cancer4Triple Negative Breast Cancer4Metastatic Breast Cancer2Breast Neoplasms2Soft Tissue Sarcoma (STS)2Breast Cancer, Metastatic1Locally Advanced Breast Cancer1Metastatic Triple Negative Breast Cancers1Metastatic HER2-positive Breast Cancer1Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer1HER2-positive Breast Cancer1HER2-positive Gastric Cancer1
All 29 conditions
Condition (as registered)Trials
Breast Cancer4
Triple Negative Breast Cancer4
Metastatic Breast Cancer2
Breast Neoplasms2
Soft Tissue Sarcoma (STS)2
Breast Cancer, Metastatic1
Locally Advanced Breast Cancer1
Metastatic Triple Negative Breast Cancers1
Metastatic HER2-positive Breast Cancer1
Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer1
HER2-positive Breast Cancer1
HER2-positive Gastric Cancer1
HER2 Positive Solid Tumors1
HER2 Amplification1
Endometrial Neoplasms1
Advanced Solid Tumor1
Metastatic Solid Tumor1
Platinum-resistant Ovarian Cancer (PROC)1
Sarcoma,Soft Tissue1
HER2-negative Breast Cancer1
Advanced Breast Cancer1
Inoperable Locally Advanced HER2-Negative Breast Cancer1
Metastatic HER2-Negative Breast Cancer1
Triple Negative Breast Cancer (TNBC)1
Breast Cancer Stage IV1
Triple -Negative Breast Cancer1
Triple-Negative Breast Cancer1
Locally Advanced or Metastatic Breast Cancer1
HR+HER2- Breast Cancer1
03

Sponsors

lead sponsor per trial
Lead sponsorTrials
BioNTech SE2
Sichuan Baili Pharmaceutical Co., Ltd.2
Hoffmann-La Roche1
ALX Oncology Inc.1
AstraZeneca1
Jazz Pharmaceuticals1
Daiichi Sankyo1
Criterium, Inc.1
Enliven Therapeutics1
Advenchen Pharmaceuticals, LLC.1
GI Innovation, Inc.1
Intensity Therapeutics, Inc.1
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.1
Guangdong Provincial People's Hospital1
Jiangsu Alphamab Biopharmaceuticals Co., Ltd1

+ 6 more sponsors in the trial list above.

04

By country register

RegisterTrialsRecruiting
Clinical trials in China146
Clinical trials in USA126
Clinical trials in UK74
Clinical trials in India10

A trial with sites in more than one country appears in each of those registers.

05

Related compounds

06

Questions about Eribulin trials

How many clinical trials are testing Eribulin?

23 current trials in our China, USA, UK and India registers name Eribulin as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.

Are Eribulin trials recruiting patients?

Yes. 11 of the 23 trials are recruiting: 6 with sites in China, 6 with sites in USA and 4 with sites in UK. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Eribulin clinical trials?

BioNTech SE (2), Sichuan Baili Pharmaceutical Co., Ltd (2), Hoffmann-La Roche (1) and ALX Oncology Inc (1), among 21 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Eribulin works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records โ€” it is not written from memory, and nothing here describes how Eribulin works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Eribulin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician โ€” our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us โ€” we correct promptly and log it.